On October 23, 2020 Quirem Medical reported a first clinical QuiremSpheres patient procedure took place with a patient dose prepared using a novel hotlab manufacturing process design, developed together with VANDERWILT Techniques (Press release, Quirem Medical, OCT 23, 2020, View Source [SID1234571203]). The new process improves radiation safety for the hotlab operators and limits the production time, preparing for further scaling-up of the production of QuiremScout and QuiremSpheres. QuiremScout is an innovative product for screening liver cancer patients before they are treated with QuiremSpheres. QuiremSpheres is a CE-marked medical device indicated for treatment of unresectable liver tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Quirem Medical and VANDERWILT Techniques have a long-standing strategic partnership during which VANDERWILT has proven to be instrumental in the optimization of the hotlab processing steps. The effectuation of this latest process innovation, including bespoke instruments and tooling, is a new milestone. It supports our hotlab operators in their daily operations, minimizing processing time while reducing dose exposure significantly." says Stuart Koelewijn, Hotlab Operations Manager of Quirem Medical BV.

"We see a strongly increasing demand for our products throughout Europe and beyond. VANDERWILT has proven to be a reliable and innovative partner to us, while we are constantly improving our internal processes to match the increasing demand and to prepare for the global expansion of our business." says Jan Sigger, CEO of Quirem Medical BV.